Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells

Leukemia
K A MargolinS J Forman

Abstract

The major cause of treatment failure in hematologic malignancies is the development of resistance to chemotherapeutic agents and the presence of clonogenic tumor cells in remission bone marrow. In the present study, we tested the optimal conditions for activation by interleukin-2 (IL-2) of endogenous bone marrow effector cells to develop cytotoxicity against solid tumor and leukemia cells and the effects of IL-2 treatment on eradication of malignant cells from the marrow product while preserving hematopoiesis. Normal donor bone marrow was contaminated with 10% A549 lung cancer cells, MCF-7 breast cancer, or EM2 leukemia cells, and then combined with peripheral blood-derived lymphokine-activated killer (LAK) cells which had been incubated in the presence of IL-2, 6000 IU/ml, for 5 days. Eradication (A549 and MCF-7) or >90% reduction in tumor cell number (EM2) was achieved upon exposure of the marrow to LAK cells but not to control, non-IL-2-exposed PBMC. The non-cross-resistance of chemotherapy and cell-mediated cytotoxicity were tested by using chemoresistant target cells for LAK cytotoxicity assays. Ara-C-resistant K562 cells were sensitive to LAK cytotoxicity, similar to sensitive controls. Similar effects were seen in daunom...Continue Reading

Citations

Sep 21, 2000·Critical Reviews in Oncology/hematology·N SabaA Keating
Aug 31, 2010·Journal of Experimental & Clinical Cancer Research : CR·Qun ZhaoLiqiao Fan
Aug 5, 2004·Photochemistry and Photobiology·Su-Juan Zhang, Zhen-Xi Zhang
Jun 2, 2000·Cancer Investigation·R D BaynesW P Peters
May 19, 2004·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Koen Van BesienRichard Champlin
Feb 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anthony S SteinStephen J Forman
Jun 1, 1997·Immunological Reviews·K A MargolinS J Forman
Aug 30, 2000·Medical Oncology·S M Blaney, D G Poplack
Feb 11, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dirk SchadendorfJedd D Wolchok

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Biology: Molecular Imaging

Molecular imaging enables noninvasive imaging of key molecules that are crucial to tumor biology. Discover the latest research in molecular imaging in cancer biology in this feed.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

© 2021 Meta ULC. All rights reserved